サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790427

抗生物質の市場規模、シェア、動向分析レポート：薬剤クラス別、タイプ別、作用機序別、地域別、セグメント別予測、2025年～2033年

Antibiotics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Fluoroquinolone), By Type (Branded Antibiotics, Generic Antibiotics), By Action Mechanism, By Region, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
抗生物質の市場規模、シェア、動向分析レポート：薬剤クラス別、タイプ別、作用機序別、地域別、セグメント別予測、2025年～2033年
出版日: 2025年07月16日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗生物質市場の概要

世界の抗生物質市場規模は2024年に530億7,000万米ドルと推定され、2033年には740億7,000万米ドルに達すると予測され、2025～2033年のCAGRは3.71%で成長すると予測され、市場成長の主要因となっています。抗生物質市場は、細菌感染症の流行によって牽引されています。

肺炎や気管支炎などの呼吸器感染症（RTI）は最も広く蔓延している感染症の一つであり、例えば2025年5月、CDCは2024～2025年のデータに基づき、米国では4700万～8,200万人のインフルエンザ罹患者、2,100万人の医療機関受診者、64万人の入院者が発生したと推定しています。毎週のインフルエンザサーベイランスと数学的モデリングから導き出されたこれらの速報値は、今シーズンの疾病負担を反映しており、しばしば抗生物質を必要とする二次的な細菌感染症を引き起こします。BMC Infectious Diseasesによると、尿路感染症（UTI）は、世界で年間1億5,000万件以上の症例があり、抗生物質使用の主要原因となっています。蜂窩織炎などの皮膚・軟部組織感染症（SSTI）も、特に外来診療において重要です。クロストリジウム・ディフィシル（Clostridium difficile）やメチシリン耐性黄色ブドウ球菌（MRSA）などの院内感染（HAI）は、さらに需要を増大させています。これらの感染症は、都市化、高齢化、抗菌薬耐性（AMR）の増加により、既存の治療法の有効性が低下していることが背景にあります。ヘルスケアへのアクセスが限られた市場での感染率の高さが抗生物質の必要性をさらに高め、耐性という課題にもかかわらず市場の成長を支えています。

抗生物質の研究開発（R&D）は、高コストと低収益性のためにハードルが高いです。新しい抗生物質の開発には多額の費用がかかり、臨床検査や規制上の要求がその負担に拍車をかける一方、治療期間が短いため収益が限られます。しかし、2025年4月にCARB-XがArrePathに370万米ドルを支払うなど、複雑な尿路感染症に焦点を当てた多剤耐性腸内細菌を標的とする新規抗生物質の開発が進んでいます。ArrePathは、AIを活用したプラットフォームにより、独自のメカニズムを持つ阻害剤を特定し、抗菌薬耐性と効果的に闘うための経口と静脈内治療の選択肢を提供する可能性があります。例えば、Pfizerは2023年にアッヴィと提携し、新規抗生物質の組み合わせを開発し、コストとリスクを分担しています。また、世界AMR研究開発ハブは、抗生物質パイプラインを強化するための国際的な取り組みを調整しています。このような対策にもかかわらず、耐性菌の発生が早く、新薬の寿命が短いという課題が残っています。このような障壁を克服し、耐性菌の増加と闘う効果的な抗生物質を確実に開発するためには、官民協力の継続が不可欠です。

抗生物質市場の主要企業は、競合を維持するために合併、提携、技術革新などの戦略を採用しています。2025年2月には、Novartisが脳卒中予防プログラムのアンソス・セラピューティクスを最大21億5,000万米ドル（契約一時金9億2,500万米ドル）で買収し、イーライ・リリーがオルガノボの炎症性腸疾患治療FXRプログラムを買収し（条件は非公開）、7億3,700万米ドルの現金資金を元手に免疫介在性疾患に特化したアルミスとアセリンの合併など、主要なバイオテクノロジー案件がありました。2023年、MerckはExscientiaと提携して6億7,400万米ドル以上を投資し、医薬品開発、製造、規制プロセスにAIを応用しました。さらに、MerckはBenevolentAIと提携し、AI創薬プラットフォームにさらに数億米ドルを投資しました。肺炎治療XacduroのFDA承認を2023年に取得したEntasis Therapeuticsのような中小企業は、ニッチ市場を対象にしています。GSKのような企業はまた、責任ある使用を奨励するために抗生物質のスチュワードシップを推進しています。しかし、ジェネリック医薬品との競合や、耐性菌の圧力にさらされる中での絶え間ない技術革新の必要性は、収益性に課題を投げかけています。こうした市場の開拓は、企業が優位性を維持するために、コスト管理と新規抗生物質の追求のバランスをとっているダイナミック市場を反映しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗生物質市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/付随市場の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 抗生物質市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析

第4章 抗生物質市場：薬剤クラス別、推定・動向分析

  • 薬剤クラス市場シェア、2024年と2033年
  • セグメントダッシュボード
  • 世界の抗生物質市場：薬剤クラス別展望
  • 2021～2033年までの市場規模と予測と動向分析
    • セファロスポリン
    • ペニシリン
    • フルオロキノロン
    • マクロライド
    • カルバペネム
    • アミノグリコシド
    • スルホンアミド
    • 7-ACA
    • その他

第5章 抗生物質市場：タイプ別、推定・動向分析

  • タイプ別市場シェア、2024年と2033年
  • セグメントダッシュボード
  • 世界の抗生物質市場：タイプ別展望
  • 2021～2033年までの市場規模と予測と動向分析
    • ブランド抗生物質
    • ジェネリック抗生物質

第6章 抗生物質市場：作用機序別、推定・動向分析

  • 作用機序市場シェア、2024年と2033年
  • セグメントダッシュボード
  • 世界の抗生物質市場：作用機序別展望
  • 2021～2033年までの市場規模と予測と動向分析
    • 細胞壁合成阻害剤
    • タンパク質合成阻害剤
    • DNA合成阻害剤
    • RNA合成阻害剤
    • ミコール酸阻害剤
    • その他

第7章 抗生物質市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2033年
  • 地域別市場ダッシュボード
  • 世界地域市場のスナップショット
  • 市場規模、予測動向分析、2021～2033年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店とチャネルパートナー一覧
    • 主要企業の市場シェア分析、2024年
    • AbbVie, Inc.
    • Pfizer Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Lupin Pharmaceuticals, Inc.
    • Viatris, Inc.
    • Melinta Therapeutics LLC
    • Cipla, Inc.
    • Shionogi & Co., Ltd.
    • KYORIN Pharmaceutical Co., Ltd.
    • GSK plc
    • Nabriva Therapeutics PLC
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 4 North America Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 5 North America Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 6 U.S. Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 7 U.S. Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 8 U.S. Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 9 Canada Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 10 Canada Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 11 Canada Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 12 Mexico Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 13 Mexico Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 15 Europe Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 17 Europe Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 18 Europe Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 19 Germany Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 20 Germany Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 21 Germany Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 22 UK Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 23 UK Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 24 UK Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 25 France Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 26 France Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 27 France Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 28 Italy Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 29 Italy Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 30 Italy Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 31 Spain Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 32 Spain Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 33 Spain Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 34 Denmark Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 35 Denmark Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 36 Denmark Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 37 Sweden Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 38 Sweden Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 39 Sweden Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 40 Norway Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 41 Norway Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 42 Norway Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 47 China Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 48 China Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 49 China Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 50 Japan Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 51 Japan Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 52 Japan Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 53 India Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 54 India Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 55 India Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 56 South Korea Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 57 South Korea Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 58 South Korea Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 59 Australia Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 60 Australia Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 61 Australia Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 62 Thailand Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 63 Thailand Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 64 Thailand Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 65 Latin America Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 67 Latin America Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 68 Latin America Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 69 Brazil Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 70 Brazil Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 71 Brazil Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 72 Argentina Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 73 Argentina Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 74 Argentina Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 75 MEA Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 77 MEA Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 78 MEA Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 79 South Africa Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 80 South Africa Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 81 South Africa Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 85 UAE Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 86 UAE Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 87 UAE Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 88 Kuwait Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 89 Kuwait Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 90 Kuwait Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Antibiotics market: market outlook
  • Fig. 14 Antibiotics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Antibiotics market driver impact
  • Fig. 20 Antibiotics market restraint impact
  • Fig. 21 Antibiotics market strategic initiatives analysis
  • Fig. 22 Antibiotics market: Drug Class movement analysis
  • Fig. 23 Antibiotics market: Drug Class outlook and key takeaways
  • Fig. 24 Cephalosporin market estimates and forecast, 2021 - 2033
  • Fig. 25 Penicillin market estimates and forecast, 2021 - 2033
  • Fig. 26 Fluoroquinolone market estimates and forecast, 2021 - 2033
  • Fig. 27 Macrolides market estimates and forecast, 2021 - 2033
  • Fig. 28 Carbapenems market estimates and forecast, 2021 - 2033
  • Fig. 29 Aminoglycosides market estimates and forecast, 2021 - 2033
  • Fig. 30 Sulfonamides market estimates and forecast, 2021 - 2033
  • Fig. 31 7-ACA market estimates and forecast, 2021 - 2033
  • Fig. 32 Others market estimates and forecast, 2021 - 2033
  • Fig. 33 Antibiotics Market: Type movement Analysis
  • Fig. 34 Antibiotics market: Type outlook and key takeaways
  • Fig. 35 Branded Antibiotics market estimates and forecasts, 2021 - 2033
  • Fig. 36 Generic Antibiotics market estimates and forecasts,2021 - 2033
  • Fig. 37 Antibiotics market: Action Mechanism movement analysis
  • Fig. 38 Antibiotics market: Action Mechanism outlook and key takeaways
  • Fig. 39 Cell Wall Synthesis Inhibitors market estimates and forecasts, 2021 - 2033
  • Fig. 40 Protein Synthesis Inhibitors market estimates and forecasts,2021 - 2033
  • Fig. 41 DNA Synthesis Inhibitors market estimates and forecasts,2021 - 2033
  • Fig. 42 RNA Synthesis Inhibitors market estimates and forecasts, 2021 - 2033
  • Fig. 43 Mycolic Acid Inhibitors market estimates and forecasts,2021 - 2033
  • Fig. 44 Others market estimates and forecasts, 2021 - 2033
  • Fig. 45 Global Antibiotics market: Regional movement analysis
  • Fig. 46 Global Antibiotics market: Regional outlook and key takeaways
  • Fig. 47 Global Antibiotics market share and leading players
  • Fig. 48 North America market share and leading players
  • Fig. 49 Europe market share and leading players
  • Fig. 50 Asia Pacific market share and leading players
  • Fig. 51 Latin America market share and leading players
  • Fig. 52 Middle East & Africa market share and leading players
  • Fig. 53 North America: SWOT
  • Fig. 54 Europe SWOT
  • Fig. 55 Asia Pacific SWOT
  • Fig. 56 Latin America SWOT
  • Fig. 57 MEA SWOT
  • Fig. 58 North America, by country
  • Fig. 59 North America
  • Fig. 60 North America market estimates and forecasts, 2021 - 2033
  • Fig. 61 U.S.
  • Fig. 62 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 63 Canada
  • Fig. 64 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 65 Mexico
  • Fig. 66 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 67 Europe
  • Fig. 68 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 69 UK
  • Fig. 70 UK market estimates and forecasts, 2021 - 2033
  • Fig. 71 Germany
  • Fig. 72 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 73 France
  • Fig. 74 France market estimates and forecasts, 2021 - 2033
  • Fig. 75 Italy
  • Fig. 76 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 77 Spain
  • Fig. 78 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 79 Denmark
  • Fig. 80 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 81 Sweden
  • Fig. 82 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 83 Norway
  • Fig. 84 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 85 Asia Pacific
  • Fig. 86 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 87 China
  • Fig. 88 China market estimates and forecasts, 2021 - 2033
  • Fig. 89 Japan
  • Fig. 90 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 91 India
  • Fig. 92 India market estimates and forecasts, 2021 - 2033
  • Fig. 93 Thailand
  • Fig. 94 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 95 South Korea
  • Fig. 96 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 97 Australia
  • Fig. 98 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 99 Latin America
  • Fig. 100 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 101 Brazil
  • Fig. 102 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 103 Argentina
  • Fig. 104 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 105 Rest of Latin America
  • Fig. 106 Rest of Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 107 Middle East and Africa
  • Fig. 108 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 109 South Africa
  • Fig. 110 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 111 Saudi Arabia
  • Fig. 112 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 113 UAE
  • Fig. 114 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 115 Kuwait
  • Fig. 116 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 117 Market share of key market players- Antibiotics market
目次
Product Code: GVR-1-68038-149-8

Antibiotics Market Summary

The global antibiotics market size was estimated at USD 53.07 billion in 2024 and is projected to reach USD 74.07 billion by 2033, growing at a CAGR of 3.71% from 2025 to 2033, major factor contributing to market growth. The antibiotics market is driven by the prevalence of bacterial infections.

Respiratory tract infections (RTIs), such as pneumonia and bronchitis, are among the most widespread, for instance, in May 2025, the CDC estimated that the U.S. experienced between 47-82 million flu illnesses, 21 million medical visits, and 640,000 hospitalizations, based on data from 2024 - 2025. These preliminary figures, derived from weekly influenza surveillance and mathematical modeling, reflect the season's disease burden, often leading to secondary bacterial infections requiring antibiotics. Urinary tract infections (UTIs) follow closely, with over 150 million cases annually worldwide, according to BMC Infectious Diseases, making them a leading cause of antibiotic use. Skin and soft tissue infections (SSTIs), such as cellulitis, are also significant, especially in outpatient care. Hospital-acquired infections (HAIs), including Clostridium difficile and methicillin-resistant Staphylococcus aureus (MRSA), further increase demand. These infections are fueled by urbanization, aging populations, and rising antimicrobial resistance (AMR), which reduces the efficacy of existing treatments. High infection rates in developing regions with limited healthcare access further amplify the need for antibiotics, sustaining market growth despite resistance challenges.

Research and development (R&D) in antibiotics face hurdles due to high costs and low profitability. Developing new antibiotics is expensive, with clinical trials and regulatory demands adding to the burden, while short treatment durations limit returns. However, initiatives such as in April 2025, CARB-X awarded ArrePath USD 3.7 million to develop a novel antibiotic targeting multidrug-resistant Enterobacterales, focusing on complicated urinary tract infections. Using an AI-driven platform, ArrePath identified inhibitors with a unique mechanism, potentially offering oral and IV treatment options to combat antimicrobial resistance effectively. For example, Pfizer partnered with AbbVie in 2023 to develop novel antibiotic combinations, sharing costs and risks. The Global AMR R&D Hub also coordinates international efforts to bolster the antibiotic pipeline. Despite these measures, challenges persist, as resistance develops quickly, reducing the lifespan of new drugs. Sustained public-private collaboration is critical to overcoming these barriers and ensuring the development of effective antibiotics to combat rising resistance.

Key players in the antibiotics market employ strategies such as mergers, partnerships, and innovation to stay competitive. In February 2025, key biotech deals included Novartis acquiring Anthos Therapeutics for up to $2.15 billion ($925 million upfront) for its stroke prevention program, Eli Lilly buying Organovo's FXR program for inflammatory bowel disease (terms undisclosed), and the merger of Alumis and Acelyrin, focusing on immune-mediated diseases with a $737 million cash runway. In 2023, Merck invested over USD 674 million partnering with Exscientia to apply AI in drug development, manufacturing, and regulatory processes. Additionally, Merck joined forces with BenevolentAI, investing hundreds of millions more in AI drug discovery platforms. Smaller firms like Entasis Therapeutics, which gained FDA approval for Xacduro in 2023 for pneumonia, target niche markets. Companies such as GSK also promote antibiotic stewardship to encourage responsible use. However, generic competition and the need for constant innovation amid resistance pressures challenge profitability. These developments reflect a dynamic market where firms balance cost management with the pursuit of novel antibiotics to maintain their edge.

Global Antibiotics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global antibiotics market report on the basis of drug class, type, action mechanism, and region:

  • Drug Class Outlook (Revenue in USD Million, 2021 - 2033)
  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolides
  • Carbapenems
  • Aminoglycosides
  • Sulfonamides
  • 7-ACA
  • Others
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded Antibiotics
  • Generic Antibiotics
  • Action Mechanism Outlook (Revenue, USD Million, 2021 - 2033)
  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Type
    • 1.2.3. Action Mechanism
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class
    • 2.2.2. Type
    • 2.2.3. Action Mechanism
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antibiotics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Development of advanced products
      • 3.2.1.2. Increasing prevalence of infectious diseases
      • 3.2.1.3. Growing collaborations for development of antibiotics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High number of patent expirations
      • 3.2.2.2. High R&D cost
  • 3.3. Antibiotics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Antibiotics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Antibiotics Market by Drug Class Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Cephalosporin
      • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Penicillin
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Fluoroquinolone
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Macrolides
      • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5. Carbapenems
      • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.6. Aminoglycosides
      • 4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.7. Sulfonamides
      • 4.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.8. 7-ACA
      • 4.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.9. Others
      • 4.4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Antibiotics Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Antibiotics Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Branded Antibiotics
      • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Generic Antibiotics
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Antibiotics Market: Action Mechanism Estimates & Trend Analysis

  • 6.1. Action Mechanism Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Antibiotics Market by Action Mechanism Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Cell Wall Synthesis Inhibitors
      • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 6.4.2. Protein Synthesis Inhibitors
      • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. DNA Synthesis Inhibitors
      • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.4. RNA Synthesis Inhibitors
      • 6.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.5. Mycolic Acid Inhibitors
      • 6.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Antibiotics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. AbbVie, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Pfizer Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Novartis AG
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Merck & Co., Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Teva Pharmaceutical Industries Ltd.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Lupin Pharmaceuticals, Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Viatris, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Melinta Therapeutics LLC
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Cipla, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Shionogi & Co., Ltd.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. KYORIN Pharmaceutical Co., Ltd.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. GSK plc
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
    • 8.3.16. Nabriva Therapeutics PLC
      • 8.3.16.1. Company overview
      • 8.3.16.2. Financial performance
      • 8.3.16.3. Product benchmarking
      • 8.3.16.4. Strategic initiatives